RBC Capital Sticks to Its Hold Rating for Jasper Therapeutics (JSPR)

Tip Ranks
2025.12.03 12:17
portai
I'm PortAI, I can summarize articles.

RBC Capital analyst Leonid Timashev maintained a Hold rating for Jasper Therapeutics with a $4.00 price target. William Blair also issued a Hold rating, while H.C. Wainwright maintained a Buy rating. Timashev, covering the Healthcare sector, has an average return of 29.3% and a 57.29% success rate on stock recommendations.

RBC Capital analyst Leonid Timashev maintained a Hold rating on Jasper Therapeutics yesterday and set a price target of $4.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Exelixis, and Jazz Pharmaceuticals. According to TipRanks, Timashev has an average return of 29.3% and a 57.29% success rate on recommended stocks.

In addition to RBC Capital, Jasper Therapeutics also received a Hold from William Blair’s Matt Phipps in a report issued yesterday. However, on the same day, H.C. Wainwright maintained a Buy rating on Jasper Therapeutics (NASDAQ: JSPR).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer